文献速递慢阻肺

慢阻肺单次中度急性加重后吸入糖皮质激素升级:获益因急性加重亚型而异

Inhaled Corticosteroid Escalation After a Single Moderate Exacerbation in COPD: Differential Benefit by Exacerbation Subtype.
PubMed 文献 · Respirology · 2026-08-27

基于韩国国民健康保险数据库的序贯目标试验模拟,纳入94,938例起始LAMA/LABA的ICS初治慢阻肺患者。单次抗生素治疗的中度急性加重后,升级ICS未降低后续急性加重风险;而单次全身糖皮质激素治疗的中度急性加重后,继续LAMA/LABA较升级ICS的急性加重风险更高(HR 1.18,95%CI 1.12-1.23)。

要点

  • 单次抗生素治疗的中度急性加重后,升级ICS未降低后续急性加重风险。
  • 单次全身糖皮质激素治疗的中度急性加重后,升级ICS与后续急性加重风险降低相关。
  • ICS升级决策应结合急性加重治疗表型,而非仅依据急性加重频率。

核心结论

  • 单次中度急性加重后ICS升级的临床获益因急性加重治疗表型而异。
  • 糖皮质激素治疗的事件中,升级ICS与后续急性加重风险降低相关;抗生素治疗的事件中未见额外获益。

研究设计与样本

  • 使用韩国国民健康保险服务数据库,识别ICS初治并起始LAMA/LABA治疗的慢阻肺患者。
  • 在LAMA/LABA治疗期间发生一次中度急性加重的患者中进行序贯目标试验模拟。
  • 采用倾向评分匹配比较ICS升级组与继续LAMA/LABA组。
  • 共94,938例患者起始LAMA/LABA治疗。

主要发现

  • 6年时超过60%患者维持双支气管扩张剂治疗。
  • 匹配分析中,单次抗生素治疗的中度急性加重后,ICS升级与后续急性加重风险降低无关。
  • 糖皮质激素治疗的中度急性加重患者中,继续LAMA/LABA较升级ICS的急性加重风险更高(HR 1.18,95%CI 1.12-1.23)。
  • 结果在按急性加重史定义的各亚组中一致。

关键数值与推荐

  • 急性加重分类:抗生素治疗(未用全身糖皮质激素)或全身糖皮质激素治疗(伴或不伴抗生素)。
  • 糖皮质激素治疗亚组中,继续LAMA/LABA vs 升级ICS的急性加重HR为1.18(95%CI 1.12-1.23)。

临床怎么用

  • 对LAMA/LABA治疗中发生单次中度急性加重的慢阻肺患者,评估急性加重治疗表型以指导ICS升级。
  • 糖皮质激素治疗的中度急性加重患者可考虑升级至含ICS治疗。
  • 抗生素治疗的中度急性加重患者升级ICS可能无额外获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: In chronic obstructive pulmonary disease (COPD), evidence supporting escalation to inhaled corticosteroid (ICS)-containing therapy after single moderate exacerbation in patients receiving dual bronchodilator therapy remains inconsistent. We aimed to evaluate whether the clinical benefit of ICS escalation differs according to the treatment phenotype of moderate exacerbations. METHODS: Using the Korean National Health Insurance Service database, we identified ICS-naïve patients with COPD initiating long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy. Sequential target trial emulations were conducted among patients who experienced one moderate exacerbation while on LAMA/LABA. Exacerbations were classified as antibiotic-treated (without systemic corticosteroids) or systemic corticosteroid-treated (with or without antibiotics). Outcomes were compared between ICS escalation and LAMA/LABA continuation groups using propensity score matching. RESULTS: Among 94,938 patients who initiated LAMA/LABA therapy, treatment persistence remained high, with over 60% maintaining dual therapy at 6 years, despite a marked decline in exacerbation-free survival. In matched analyses, ICS escalation after single antibiotic-treated exacerbations was not associated with reduced subsequent exacerbation risk. In contrast, among patients with steroid-treated moderate exacerbations, continuation of LAMA/LABA was associated with a higher risk of exacerbations (HR 1.18, 95% CI 1.12-1.23), compared with escalation to ICS-containing therapy. Findings were consistent across subgroups defined by exacerbation history. CONCLUSION: In this large real-world COPD cohort, the benefit of ICS escalation after single moderate exacerbation varied by exacerbation treatment phenotype. Steroid-treated events were associated with a reduced subsequent exacerbation with ICS escalation, whereas antibiotic-treated events did not confer additional benefit from ICS, supporting a more precise approach to ICS escalation beyond exacerbation frequency alone.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Shin SH, Heo J, Jung JY, et al. Inhaled Corticosteroid Escalation After a Single Moderate Exacerbation in COPD: Differential Benefit by Exacerbation Subtype. Respirology. 2026. PMID: 42657955. doi:10.1002/resp.70300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。